Tocilizumab
- PDF / 141,286 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 111 Downloads / 196 Views
1
Tocilizumab Various toxicities: 2 case reports Two patients with multicentric Castleman disease (MCD) developed various toxicities during treatment with tocilizumab [route not stated]. A 16.5-year-old boy commenced tocilizumab 8 mg/kg infused once every 2 weeks after previous chemotherapy yielded no clinical response. After 10 months of treatment, the interval was extended to once every 3 weeks for a 5-month period, then one every 4 weeks for 1 year, and then once every 5 weeks. At last follow-up, he had been receiving tocilizumab for 3 years. Adverse effects included occasional headaches, low platelet counts and low fibrin levels [duration of treatment to reactions onset and outcome not stated]. He also experienced an episode of intercostal herpes zoster after 10 months of treatment. A 10.8-year-old girl started treatment with tocilizumab 8 mg/kg every 2 weeks. She developed sustained mild thrombocytopenia and hypofibrinaemia [duration of treatment to reactions onset and outcome not stated]. At last follow-up, she had been receiving tocilizumab for 8 months. Author comment: "Sustained thrombocytopenia and hypofibrinemia are possibly side effects of tocilizumab." Galeotti C, et al. Sustained remission of multicentric castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. Molecular Cancer Therapeutics 11: 1623-1626, No. 8, Aug 2012. Available from: URL: http:// 803078270 dx.doi.org/10.1158/1535-7163.MCT-11-0972 - France
0114-9954/10/1424-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 20 Oct 2012 No. 1424
Data Loading...
